Takano S, Moriguchi M, Seki N, Higaki T, Watanabe Y, Takahashi T, Ito Y, Oishi H, Nakata Y, Kono S
Third Dept. of Surgery, Nihon University School of Medicine.
Gan To Kagaku Ryoho. 1994 Sep;21(13):2176-8.
We performed portal infusion chemotherapy using a reservoir for prevention of recurrence in residual liver after hepatectomy for metastases from colo-rectal cancer. To study the usefulness of portal infusion chemotherapy, the period from hepatectomy to recurrence in residual liver was investigated by three treatment groups for H2 cases; (a) a group of systemic chemotherapy, (b) a group of arterial infusion chemotherapy and (c) a portal infusion chemotherapy group. Treatment in (a) group was for 204 +/- 98.2 days (n = 6), in (b) group for 343.0 +/- 238.3 days (n = 8) and in (c) group for 961.0 +/- 1,172.4 days (n = 5). There was no statistically significant difference in the three groups, but (c) group had a better result in recurrence in residual liver. As for prevention of recurrence in residual liver after re-hepatectomy, there was no significant difference in the three groups, but (c) group had the longest survival.
我们使用储液器进行门静脉灌注化疗，以预防结直肠癌肝转移灶肝切除术后残肝复发。为研究门静脉灌注化疗的有效性，对H2期病例按三个治疗组研究了从肝切除到残肝复发的时间；(a)全身化疗组，(b)动脉灌注化疗组，(c)门静脉灌注化疗组。(a)组治疗时间为204±98.2天（n = 6），(b)组为343.0±238.3天（n = 8），(c)组为961.0±1,172.4天（n = 5）。三组之间无统计学显著差异，但(c)组在残肝复发方面结果更好。至于再次肝切除术后预防残肝复发，三组之间无显著差异，但(c)组生存时间最长。
